Stock Financial Ratios

GNMX / Aevi Genomic Medicine, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)44.66
Enterprise Value ($M)22.95
Book Value ($M)34.98
Book Value / Share0.99
Price / Book1.27
NCAV ($M)34.98
NCAV / Share0.99
Price / NCAV5.33
Income Statement (mra) ($M)
Net Income-41.90
Balance Sheet (mrq) ($M)
Cash & Equivalents14.96
Cash / Share0.43
Quick Ratio7.20
Current Ratio7.20
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.20
Return on Assets (ROA)-1.03
Return on Equity (ROE)-1.20
Identifiers and Descriptors
Central Index Key (CIK)1138776
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)59.33
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Liabilities Current Per Share0.20
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Additional Paid In Capital Per Share6.20
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Per Share0.20
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Liabilities And Stock Equity Per Share0.48
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Assets Other Current Per Share0.00
Assets Current Per Share0.45
Cash And Equivalents Per Share0.43
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Assets Other Non Current Per Share0.03
Inventory Per Share0.00
Retained Earnings Per Share-5.91
Accounts Payable Per Share0.10
Inventory Work In Progress Per Share0.00
Assets Per Share0.46
Property Plant And Equipment Net Per Share0.00
Equity Per Share0.29
Treasury Stock Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Cash Per Share0.43

Related News Stories

ROTY Edition 1 Volume 58: Increasing Contender Coverage And Trades

2017-12-05 seekingalpha
We are swapping another current loser for a Contender that appears to be setting up for a catalyst-filled 2018. (130-5)

Aevi Genomic Medicine: Several Catalysts Coming In The Middle Of 2018

2017-11-29 seekingalpha
The share price has come back down after a pop that was due to insider buying. (16-7)

A Current Look At The ROTY Contenders List

2017-11-25 seekingalpha
Today, we focus on the Contenders List, our constantly changing "bank" of ideas that are either setting up now or could offer an entry point later on. (325-3)

Can Pharma Succeed In A Condition Impacting 1 In 68 Children?

2017-10-31 seekingalpha
The pharmaceutical industry has struggled to address autism due to its heterogeneity, with only two medications approved for any autism symptom - both of which were blockbusters. (104-5)

Your Daily Pharma Scoop: Gilead's Brave New World, AZN's Lynparza SNDA, RXDX Entrectinib Shows Positive Results

2017-10-19 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (701-5)

CUSIP: 58436Q203